Dyne Therapeutics Inc (DYN)

$8.18 -0.58 (-6.62%)
Market Cap 995.72M
Revenue (ttm) 0.00
Net Income (ttm) -317.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,672,800
Avg Vol 2,831,980
Day's Range N/A - N/A
Shares Out 113.67M
Stochastic %K 4%
Beta 1.08
Analysts Strong Sell
Price Target $40.35

Company Profile

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therap...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 786 8230
Fax: 781 786 8866
Address:
1560 Trapelo Road, Waltham, United States
Chomo
Chomo Jul. 7 at 9:53 PM
$DYN no buyers in this one.
0 · Reply
Jewstock
Jewstock Jul. 7 at 4:25 PM
$DYN will be averaging down here
0 · Reply
deca90
deca90 Jul. 7 at 4:15 PM
$DYN I read good things about this stock got in at $8.76 let’s see
0 · Reply
Sam201
Sam201 Jul. 7 at 3:17 PM
$DYN loaded another 500 shares. Be slow..
0 · Reply
Jewstock
Jewstock Jul. 7 at 1:49 PM
$DYN offering rlly hurt us
0 · Reply
TradingLaboratory
TradingLaboratory Jul. 5 at 1:39 AM
$DYN Glad they got the offering out the way
0 · Reply
Sam201
Sam201 Jul. 3 at 1:52 PM
$DYN getting back.. but will be slow!
0 · Reply
RunnerSignals
RunnerSignals Jul. 2 at 9:19 PM
$DYN $VSTM bounce from oversold with fresh volume and momentum. Watch support because timing is everything!
0 · Reply
Jewstock
Jewstock Jul. 2 at 3:48 PM
$DYN the recovery has begun 🤞🏻
0 · Reply
bmwood86
bmwood86 Jul. 2 at 1:39 PM
$DYN
1 · Reply
Latest News on DYN
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Jul 2, 2025, 4:01 PM EDT - 5 days ago

Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Tesla, Progress Software, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Jul 1, 2025, 9:00 AM EDT - 6 days ago

Tesla, Progress Software, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

PRGS TSLA

Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock

Jun 30, 2025, 9:45 PM EDT - 7 days ago

Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

Jun 30, 2025, 4:05 PM EDT - 7 days ago

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital

Jun 30, 2025, 4:01 PM EDT - 7 days ago

Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital

Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - DYN

Jun 24, 2025, 3:43 AM EDT - 13 days ago

Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - DYN

Dyne Therapeutics - Emergence As A Superior DM1 / DMD Player Warrants Rating Upgrade

Jun 18, 2025, 11:08 AM EDT - 19 days ago

Dyne Therapeutics - Emergence As A Superior DM1 / DMD Player Warrants Rating Upgrade

Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – DYN

Jun 17, 2025, 1:35 PM EDT - 20 days ago

Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – DYN

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting

Jun 17, 2025, 7:00 AM EDT - 20 days ago

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting

Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET

Jun 16, 2025, 4:05 PM EDT - 21 days ago

Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET

Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress

Jun 5, 2025, 7:30 AM EDT - 4 weeks ago

Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress

Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 8, 2025, 7:30 AM EDT - 2 months ago

Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy

Apr 24, 2025, 7:30 AM EDT - 2 months ago

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy

Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments

Apr 15, 2025, 7:30 AM EDT - 2 months ago

Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 14, 2025, 4:30 PM EDT - 3 months ago

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer

Mar 20, 2025, 4:30 PM EDT - 3 months ago

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer

Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer

Mar 20, 2025, 4:10 PM EDT - 3 months ago

Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer

Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months

Mar 16, 2025, 7:00 PM EDT - 4 months ago

Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months

Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker

Mar 13, 2025, 9:09 AM EDT - 4 months ago

Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker

Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks

Mar 12, 2025, 3:05 PM EDT - 4 months ago

Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks

Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum

Mar 11, 2025, 7:30 AM EDT - 4 months ago

Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum

Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Feb 27, 2025, 7:30 AM EST - 4 months ago

Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference

Feb 14, 2025, 4:05 PM EST - 5 months ago

Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference

Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 3, 2025, 7:30 AM EST - 5 months ago

Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Jan 21, 2025, 7:30 AM EST - 5 months ago

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Why Is Neuromuscular-Focused Dyne Therapeutics Stock Trading Lower On Friday?

Jan 10, 2025, 1:40 PM EST - 6 months ago

Why Is Neuromuscular-Focused Dyne Therapeutics Stock Trading Lower On Friday?

Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026

Jan 10, 2025, 6:30 AM EST - 6 months ago

Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026

Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 9, 2025, 7:30 AM EST - 6 months ago

Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET

Jan 8, 2025, 4:05 PM EST - 6 months ago

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET

Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases

Nov 11, 2024, 6:15 PM EST - 8 months ago

Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases

Dyne Therapeutics to Present at Upcoming Investor Conferences

Nov 7, 2024, 4:15 PM EST - 8 months ago

Dyne Therapeutics to Present at Upcoming Investor Conferences

Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm

Nov 3, 2024, 11:00 AM EST - 8 months ago

Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm

Dyne Therapeutics Inc Is Being Sued For Securities Fraud And Shareholders With Losses Are Urged To Contact The Schall Law Firm

Oct 31, 2024, 11:00 AM EDT - 8 months ago

Dyne Therapeutics Inc Is Being Sued For Securities Fraud And Shareholders With Losses Are Urged To Contact The Schall Law Firm

Dyne Therapeutics Inc May Have Committed Securities Fraud And Stockholders With Losses Are Urged To Reach Out To The Schall Law Firm

Oct 29, 2024, 11:00 AM EDT - 8 months ago

Dyne Therapeutics Inc May Have Committed Securities Fraud And Stockholders With Losses Are Urged To Reach Out To The Schall Law Firm

Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Urged To Contact The Schall Law Firm

Oct 26, 2024, 11:00 AM EDT - 9 months ago

Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Urged To Contact The Schall Law Firm

Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Impacted Shareholders Are Urged To Contact The Schall Law Firm

Oct 20, 2024, 11:00 AM EDT - 9 months ago

Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Impacted Shareholders Are Urged To Contact The Schall Law Firm

The Schall Law Firm Encourages Investor Participation In An Inquiry Into Dyne Therapeutics, Inc. For Securities Related Infractions

Oct 17, 2024, 11:00 AM EDT - 9 months ago

The Schall Law Firm Encourages Investor Participation In An Inquiry Into Dyne Therapeutics, Inc. For Securities Related Infractions

Dyne Therapeutics Inc Is Being Investigated For Possible Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm

Oct 16, 2024, 11:00 AM EDT - 9 months ago

Dyne Therapeutics Inc Is Being Investigated For Possible Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm

Dyne Therapeutics Inc Is Being Investigated For Possible Securities Fraud And Affected Shareholders Are Urged To Help The Schall Law Firm

Oct 14, 2024, 11:00 AM EDT - 9 months ago

Dyne Therapeutics Inc Is Being Investigated For Possible Securities Fraud And Affected Shareholders Are Urged To Help The Schall Law Firm

Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases

Oct 9, 2024, 7:30 AM EDT - 9 months ago

Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases

The Schall Law Firm Invites Investor Participation In An Inquiry Into Dyne Therapeutics, Inc. For Violating Securities Laws

Sep 29, 2024, 11:00 AM EDT - 10 months ago

The Schall Law Firm Invites Investor Participation In An Inquiry Into Dyne Therapeutics, Inc. For Violating Securities Laws

Chomo
Chomo Jul. 7 at 9:53 PM
$DYN no buyers in this one.
0 · Reply
Jewstock
Jewstock Jul. 7 at 4:25 PM
$DYN will be averaging down here
0 · Reply
deca90
deca90 Jul. 7 at 4:15 PM
$DYN I read good things about this stock got in at $8.76 let’s see
0 · Reply
Sam201
Sam201 Jul. 7 at 3:17 PM
$DYN loaded another 500 shares. Be slow..
0 · Reply
Jewstock
Jewstock Jul. 7 at 1:49 PM
$DYN offering rlly hurt us
0 · Reply
TradingLaboratory
TradingLaboratory Jul. 5 at 1:39 AM
$DYN Glad they got the offering out the way
0 · Reply
Sam201
Sam201 Jul. 3 at 1:52 PM
$DYN getting back.. but will be slow!
0 · Reply
RunnerSignals
RunnerSignals Jul. 2 at 9:19 PM
$DYN $VSTM bounce from oversold with fresh volume and momentum. Watch support because timing is everything!
0 · Reply
Jewstock
Jewstock Jul. 2 at 3:48 PM
$DYN the recovery has begun 🤞🏻
0 · Reply
bmwood86
bmwood86 Jul. 2 at 1:39 PM
$DYN
1 · Reply
ahmedmn
ahmedmn Jul. 1 at 7:12 PM
$DYN good time for a quick short
1 · Reply
Jewstock
Jewstock Jul. 1 at 4:58 PM
$DYN nibbling shares
0 · Reply
OpenOutcrier
OpenOutcrier Jul. 1 at 12:39 PM
$DYN (-12.1% pre) Dyne Therapeutics Inc. (DYN) Announces Proposed $200M Share Offering https://ooc.bz/l/69164
0 · Reply
DonCorleone77
DonCorleone77 Jul. 1 at 10:21 AM
$DYN Dyne Therapeutics 24.2M share Spot Secondary priced at $8.25 The deal range was $8.25-$9.00. Morgan Stanley, Jefferies, Stifel and Guggenheim acted as joint book running managers for the offering.
0 · Reply
LadsAndGents
LadsAndGents Jul. 1 at 4:59 AM
$DYN to revisit ATL because of ATM 😂
0 · Reply
Jewstock
Jewstock Jun. 30 at 9:17 PM
$DYN $200M offering thank god I have a spare 200M sitting around
0 · Reply
Jewstock
Jewstock Jun. 30 at 9:14 PM
$DYN what happened wtf
0 · Reply
50bps
50bps Jun. 30 at 8:29 PM
$DYN its that time in the cycle
0 · Reply
Sam201
Sam201 Jun. 30 at 8:14 PM
$DYN bummer… they have some good news but want to raise money first. Out.. will get back .
0 · Reply
RNASequencing
RNASequencing Jun. 30 at 8:09 PM
$DYN ugly raise
0 · Reply
Sam201
Sam201 Jun. 30 at 4:08 PM
$DYN started a position- 4k shares! This should see 30ish!
1 · Reply
Jewstock
Jewstock Jun. 26 at 7:57 PM
$DYN fuckkkkkkk should I buy more
1 · Reply